Return to home page
Searching: Muskingum library catalog
We are currently experiencing delivery delays for items requested from other institutions while transitioning to a new statewide delivery service. Please contact your library with questions or advice about alternative resources. Thank you for your patience!
  Previous Record Previous Item Next Item Next Record
  Reviews, Summaries, etc...
Author Boname, Morgan L.,
Title Advancing the discipline of regulatory science for medical product development : an update on progress and a forward-looking agenda : workshop summary / Morgan L. Boname, Amanda Wagner Gee, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine.
Imprint Washington, DC : National Academies Press, [2016]

Author Boname, Morgan L.,
Subject United States. Food and Drug Administration.
Drug development -- Technological innovations -- United States.
Pharmaceutical policy -- United States.
Drug Discovery.
Government Regulation.
Consumer Product Safety.
Drug and Narcotic Control.
Equipment and Supplies.
Therapies, Investigational.
United States.
Alt Name Gee, Amanda Wagner,
Claiborne, Anne B.,
National Academies of Sciences, Engineering, and Medicine (U.S.). Forum on Drug Discovery, Development, and Translation,
Advancing the Discipline of Regulatory Science for Medical Product Development: an Update on Progress and a Forward-Looking Agenda (Workshop) (2015 : Washington, D.C.)
Description 1 online resource (1 PDF file (xvi, 87 pages)) : illustrations
Bibliography Note Includes bibliographical references.
Summary The field of endeavors known as "regulatory science" has grown out of the need to link and integrate knowledge within and among basic science research, clinical research, clinical medicine, and other specific scientific disciplines whose focus, aggregation, and ultimate implementation could inform biomedical product development and regulatory decision making. Substantial efforts have been devoted to defining regulatory science and communicating its value and role across the scientific and regulatory ecosystems. Investments are also being made in technology infrastructure, regulatory systems, and workforce development to support and advance this burgeoning discipline. In October 2015, the National Academies of Sciences, Engineering, and Medicine held a public workshop to facilitate dialogue among stakeholders about the current state and scope of regulatory science, opportunities to address barriers to the discipline's success, and avenues for fostering collaboration across sectors. Participants explored key needs for strengthening the discipline of regulatory science, including considering what are the core components of regulatory science infrastructure to foster innovation in medical product development. This report summarizes the presentations and discussions from the workshop.
Note This activity was supported by AbbVie, Inc.; the American Diabetes Association; American Society of Microbiology; Amgen Inc. (Contract No. GHCCOPS-CSARF-63987); Association of American Medical Colleges; AstraZeneca; Baxter BioScience; Burroughs Wellcome Fund (Contract No. 1015149); Critical Path Institute; Doris Duke Charitable Foundation (Contract No. 2015103); Eli Lilly & Co.; FasterCures; Friends of Cancer Research; GlaxoSmithKline (Contract No. 005319); Johnson & Johnson; Merck & Co., Inc. (Contract No. CMO-141224-000649); National Institutes of Health (NIH) (Contract No. HHSN263201200074I; Task Order HHSN26300023): National Cancer Institute (NIH), National Center for Advancing Translational Sciences (NIH), National Institute of Allergy and Infectious Diseases (NIH), National Institute of Mental Health (NIH), and National Institute of Neurological Disorders and Stroke (NIH); New England Journal of Medicine; Pfizer Inc.; Sanofi; Takeda Pharmaceuticals (Contract No. 53108); and U.S. Food and Drug Administration (Contract No. 1R13FD005496-01). Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.
Online resource; title from PDF title page (viewed on October 31, 2016).
Contents Introduction -- Characterizing the Implementation science landscape -- Regulatory science applications: using case studies to focus on approaches to advance the discipline -- Regulatory science infrastructure and workforce -- Challenges and opportunities in regulatory science -- Appendix A: Bibliography -- Appendix B: Workshop agenda -- Appendix C: Participant biographies.
ISBN 9780309438841
OCLC # 953532375
Additional Format Print version: Advancing the discipline of regulatory science for medical product development. Washington, DC : the National Academies Press, [2016] 0309438845 (OCoLC)953843252

If you experience difficulty accessing or navigating this content, please contact the OPAL Support Team